Cenobamate FDA-Approved for Partial-Onset Seizures

SK Life Science’s sodium channel antagonist cenobamate was approved based on data from pivotal trials in nearly 2000 patients in which it reduced the median number of seizures per 28 days.

from Front page feed https://ift.tt/35BxLy2